Get Live Data

The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Latest Share Chat

  2. Share Prices
  3. Astrazeneca Share Price
  4. Astrazeneca Share Regulatory News
  5. Form 8.3 - Astrazeneca Plc

Pin to quick picksAstrazeneca Regulatory News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: 0.00 (0.00%)
Spread: 2.00 (0.017%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Astrazeneca Plc

27 May 2014 16:14

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Identity of the person whose positions/dealings Barclays PLC.
are being disclosed:
(b) Owner or controller of interest and short
positions disclosed, if different from 1(a):
(c) Name of offeror/offeree in relation to whose ASTRAZENECA PLC
relevant securities this form relates:
(d) If an exempt fund manager connected with an
offeror/offeree, state this and specify identity of
offeror/offeree:
(e) Date position held/dealing undertaken: 26 May 2014
(f) Has the discloser previously disclosed, or are YES:
they today disclosing, under the Code in respect PFIZER INC
of any other party to this offer?

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security: ORD
Interests Short Positions
Number (%) Number (%)
(1) Relevant securities owned
and/or controlled: 14,893,323 1.17% 7,447,422 0.59%
(2) Derivatives (other than
options): 1,148,635 0.09% 6,559,673 0.52%
(3) Options and agreements to
purchase/sell: 1,773,076 0.14% 4,410,883 0.35%
(4) TOTAL:
17,815,034 1.40% 18,417,978 1.46%

All interests and all short positions should be disclosed.

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other executive options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

(a) Purchases and sales

Class of relevant Purchase/sale Number of Price per unit
security securities
ORD Purchase 36 469.2400 SEK
ORD Purchase 36 469.4000 SEK
ORD Purchase 78 467.4000 SEK
ORD Purchase 97 474.5850 SEK
ORD Purchase 100 53.0500 EUR
ORD Purchase 100 53.1200 EUR
ORD Purchase 259 470.5830 SEK
ORD Purchase 315 473.5749 SEK
ORD Purchase 378 473.7285 SEK
ORD Purchase 399 466.8000 SEK
ORD Purchase 460 469.5889 SEK
ORD Purchase 477 466.8981 SEK
ORD Purchase 1,035 473.6211 SEK
ORD Purchase 1,117 472.9087 SEK
ORD Purchase 2,521 477.6674 SEK
ORD Purchase 8,352 474.3893 SEK
ORD Purchase 25,165 469.5164 SEK
ORD Purchase 155,000 472.4234 SEK
ORD Sale 36 469.2400 SEK
ORD Sale 36 469.4000 SEK
ORD Sale 72 469.3200 SEK
ORD Sale 78 467.4000 SEK
ORD Sale 100 53.0500 EUR
ORD Sale 100 53.1200 EUR
ORD Sale 188 471.2561 SEK
ORD Sale 399 466.8000 SEK
ORD Sale 477 466.8981 SEK
ORD Sale 490 475.4000 SEK
ORD Sale 496 478.0322 SEK
ORD Sale 820 474.2000 SEK
ORD Sale 1,200 476.2122 SEK
ORD Sale 8,847 469.5479 SEK
ORD Sale 10,162 474.1767 SEK
ORD Sale 16,343 469.5290 SEK

(b) Derivatives transactions (other than options)

Class of Product Nature of dealing Number of Price per
relevant description reference unit
security securities
ORD SWAP Short 155,000 472.4234 SEK

(c) Options transactions in respect of existing securities

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type

e.g. American, European etc.

Expiry date Option money paid/ received per unit

(ii) Exercising

Class of relevant security Product description

e.g. call option

Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing

e.g. subscription, conversion

Details Price per unit (if applicable)

The currency of all prices and other monetary amounts should be stated.

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state “none”

NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

NONE

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached? YES
Date of disclosure: 27 May 2014
Contact name: Rajesh Muthanna
Telephone number: 020 3555 4634

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

143221.01

SUPPLEMENTAL FORM 8 (OPEN POSITIONS)

DETAILS OF OPEN OPTION AND DERIVATIVE POSITIONS, AGREEMENTS TO PURCHASE OR SELL ETC.

Note 5(i) on Rule 8 of the Takeover Code (the “Code”)

1. KEY INFORMATION

Identity of the person whose positions/dealings Barclays PLC.
are being disclosed:
Name of offeror/offeree in relation to whose ASTRAZENECA PLC
relevant securities this from relates:

2. OPTIONS AND DERIVATIVES

Class Product Writing, Number Exercise Type Expiry
of description purchasing, of price date
relevant selling, securities per unit
security varying etc to which
option
relates
ORD Futures Selling -150,000 2.4600 18 Dec 2015
ORD Futures Purchased 21,000 3749.5637 18 Jul 2014
ORD Put Options Purchased -100,000 4500.0000 American 20 Jun 2014
ORD Put Options Written 200,000 4200.0000 American 20 Jun 2014
ORD Call Options Purchased 150,000 4200.0000 American 20 Jun 2014
ORD Call Options Purchased 50,000 4600.0000 American 20 Jun 2014
ORD Call Options Written -150,000 4200.0000 American 19 Sep 2014
ORD Call Options Written -4,000 4400.0000 American 20 Jun 2014
ORD Call Options Written -45,000 4500.0000 American 20 Jun 2014
ORD Call Options Written -50,000 4600.0000 American 19 Sep 2014
ORD Put Options Purchased -100 25.0000 American 17 Jan 2015
ORD Put Options Purchased -400 30.0000 American 17 Jan 2015
ORD Put Options Purchased -1,300 30.0000 American 15 Jan 2016
ORD Put Options Purchased -700 35.0000 American 17 Jan 2015
ORD Put Options Purchased -1,100 37.5000 American 17 Jan 2015
ORD Put Options Purchased -1,100 40.0000 American 17 Jan 2015
ORD Put Options Purchased -200 42.5000 American 17 Jan 2015
ORD Put Options Purchased -6,200 47.5000 American 17 Jan 2015
ORD Put Options Purchased -100 50.0000 American 15 Jan 2016
ORD Put Options Purchased -400 55.0000 American 15 Jan 2016
ORD Put Options Purchased -1,000 57.5000 American 17 Jan 2015
ORD Put Options Purchased -600 60.0000 American 18 Oct 2014
ORD Put Options Purchased -400 60.0000 American 17 Jan 2015
ORD Put Options Purchased -10,000 62.5000 American 17 Jan 2015
ORD Put Options Purchased -97,600 65.0000 American 21 Jun 2014
ORD Put Options Purchased -191,900 65.0000 American 19 Jul 2014
ORD Put Options Purchased -325,000 65.0000 American 17 Jan 2015
ORD Put Options Purchased -7,900 67.5000 American 21 Jun 2014
ORD Put Options Purchased -51,700 67.5000 American 19 Jul 2014
ORD Put Options Purchased -400 67.5000 American 17 Jan 2015
ORD Put Options Purchased -1,792 70.0000 American 20 Jun 2014
ORD Put Options Purchased -800 70.0000 American 18 Oct 2014
ORD Put Options Purchased -11,100 70.0000 American 17 Jan 2015
ORD Put Options Purchased -3,225 72.5000 American 20 Jun 2014
ORD Put Options Purchased -58,000 72.5000 American 21 Jun 2014
ORD Put Options Purchased -280,000 72.5000 American 19 Jul 2014
ORD Put Options Purchased -2,687 75.0000 American 20 Jun 2014
ORD Put Options Purchased -50,000 75.0000 American 21 Jun 2014
ORD Put Options Purchased -3,000 80.0000 American 20 Jun 2014
ORD Put Options Purchased -1,343 80.0000 American 18 Jul 2014
ORD Put Options Purchased -5,300 80.0000 American 19 Jul 2014
ORD Put Options Purchased -400 85.0000 American 19 Jul 2014
ORD Put Options Purchased -4,600 85.0000 American 18 Oct 2014
ORD Put Options Written 600 35.0000 American 17 Jan 2015
ORD Put Options Written 300 35.0000 American 15 Jan 2016
ORD Put Options Written 1,500 40.0000 American 15 Jan 2016
ORD Put Options Written 2,500 45.0000 American 17 Jan 2015
ORD Put Options Written 100 47.5000 American 17 Jan 2015
ORD Put Options Written 300 50.0000 American 19 Jul 2014
ORD Put Options Written 1,000 50.0000 American 18 Oct 2014
ORD Put Options Written 100 50.0000 American 17 Jan 2015
ORD Put Options Written 300 52.5000 American 17 Jan 2015
ORD Put Options Written 2,400 55.0000 American 19 Jul 2014
ORD Put Options Written 200 55.0000 American 18 Oct 2014
ORD Put Options Written 400 57.5000 American 19 Jul 2014
ORD Put Options Written 1,000 57.5000 American 18 Oct 2014
ORD Put Options Written 1,500 57.5000 American 17 Jan 2015
ORD Put Options Written 4,900 60.0000 American 21 Jun 2014
ORD Put Options Written 1,800 60.0000 American 19 Jul 2014
ORD Put Options Written 10,200 60.0000 American 17 Jan 2015
ORD Put Options Written 1,100 60.0000 American 15 Jan 2016
ORD Put Options Written 34,000 62.5000 American 21 Jun 2014
ORD Put Options Written 100 62.5000 American 19 Jul 2014
ORD Put Options Written 2,700 62.5000 American 18 Oct 2014
ORD Put Options Written 6,600 62.5000 American 17 Jan 2015
ORD Put Options Written 8,000 65.0000 American 21 Jun 2014
ORD Put Options Written 3,400 65.0000 American 18 Oct 2014
ORD Put Options Written 8,700 65.0000 American 17 Jan 2015
ORD Put Options Written 14,700 67.5000 American 18 Oct 2014
ORD Put Options Written 77,100 70.0000 American 21 Jun 2014
ORD Put Options Written 800 70.0000 American 19 Jul 2014
ORD Put Options Written 3,583 70.0000 American 17 Oct 2014
ORD Put Options Written 2,100 70.0000 American 18 Oct 2014
ORD Put Options Written 1,400 70.0000 American 17 Jan 2015
ORD Put Options Written 195,900 72.5000 American 21 Jun 2014
ORD Put Options Written 19,600 72.5000 American 19 Jul 2014
ORD Put Options Written 400 72.5000 American 17 Jan 2015
ORD Put Options Written 20,300 75.0000 American 21 Jun 2014
ORD Put Options Written 5,328 75.0000 American 18 Jul 2014
ORD Put Options Written 114,400 75.0000 American 19 Jul 2014
ORD Put Options Written 3,700 75.0000 American 17 Jan 2015
ORD Put Options Written 2,500 77.5000 American 21 Jun 2014
ORD Put Options Written 3,582 77.5000 American 18 Jul 2014
ORD Put Options Written 3,900 77.5000 American 19 Jul 2014
ORD Put Options Written 500 77.5000 American 18 Oct 2014
ORD Put Options Written 55,000 80.0000 American 21 Jun 2014
ORD Put Options Written 200 80.0000 American 18 Oct 2014
ORD Put Options Written 1,000 82.5000 American 17 Jan 2015
ORD Call Options Purchased 200 30.0000 American 17 Jan 2015
ORD Call Options Purchased 3,000 55.0000 American 17 Jan 2015
ORD Call Options Purchased 200 60.0000 American 15 Jan 2016
ORD Call Options Purchased 500 62.5000 American 19 Jul 2014
ORD Call Options Purchased 1,200 65.0000 American 17 Jan 2015
ORD Call Options Purchased 198,200 67.5000 American 21 Jun 2014
ORD Call Options Purchased 10,000 67.5000 American 19 Jul 2014
ORD Call Options Purchased 13,400 70.0000 American 21 Jun 2014
ORD Call Options Purchased 11,100 70.0000 American 19 Jul 2014
ORD Call Options Purchased 100 70.0000 American 15 Jan 2016
ORD Call Options Purchased 1,792 72.5000 American 20 Jun 2014
ORD Call Options Purchased 65,900 72.5000 American 21 Jun 2014
ORD Call Options Purchased 8,061 75.0000 American 20 Jun 2014
ORD Call Options Purchased 2,400 75.0000 American 17 Jan 2015
ORD Call Options Purchased 2,687 77.5000 American 20 Jun 2014
ORD Call Options Purchased 3,000 80.0000 American 20 Jun 2014
ORD Call Options Purchased 106,500 80.0000 American 21 Jun 2014
ORD Call Options Purchased 1,343 80.0000 American 18 Jul 2014
ORD Call Options Purchased 185,000 80.0000 American 19 Jul 2014
ORD Call Options Purchased 11,100 85.0000 American 19 Jul 2014
ORD Call Options Purchased 700 85.0000 American 18 Oct 2014
ORD Call Options Purchased 4,600 85.0000 American 17 Jan 2015
ORD Call Options Purchased 3,800 90.0000 American 21 Jun 2014
ORD Call Options Purchased 13,800 90.0000 American 19 Jul 2014
ORD Call Options Purchased 95,000 90.0000 American 18 Oct 2014
ORD Call Options Purchased 1,100 90.0000 American 17 Jan 2015
ORD Call Options Purchased 8,700 95.0000 American 18 Oct 2014
ORD Call Options Written -300 52.5000 American 15 Jan 2016
ORD Call Options Written -200 57.5000 American 17 Jan 2015
ORD Call Options Written -800 60.0000 American 19 Jul 2014
ORD Call Options Written -4,100 60.0000 American 17 Jan 2015
ORD Call Options Written -1,500 62.5000 American 17 Jan 2015
ORD Call Options Written -13,500 65.0000 American 19 Jul 2014
ORD Call Options Written -1,000 65.0000 American 18 Oct 2014
ORD Call Options Written -400 65.0000 American 15 Jan 2016
ORD Call Options Written -500 67.5000 American 19 Jul 2014
ORD Call Options Written -100 67.5000 American 18 Oct 2014
ORD Call Options Written -500 67.5000 American 17 Jan 2015
ORD Call Options Written -100 70.0000 American 21 Jun 2014
ORD Call Options Written -3,000 70.0000 American 18 Oct 2014
ORD Call Options Written -896 70.0000 American 16 Jan 2015
ORD Call Options Written -12,600 70.0000 American 17 Jan 2015
ORD Call Options Written -4,800 72.5000 American 21 Jun 2014
ORD Call Options Written -7,400 72.5000 American 19 Jul 2014
ORD Call Options Written -2,200 72.5000 American 18 Oct 2014
ORD Call Options Written -700 72.5000 American 17 Jan 2015
ORD Call Options Written -49,200 75.0000 American 21 Jun 2014
ORD Call Options Written -4,000 75.0000 American 19 Jul 2014
ORD Call Options Written -9,100 75.0000 American 18 Oct 2014
ORD Call Options Written -6,270 75.0000 American 16 Jan 2015
ORD Call Options Written -142,700 77.5000 American 21 Jun 2014
ORD Call Options Written -31,900 77.5000 American 19 Jul 2014
ORD Call Options Written -2,000 77.5000 American 18 Oct 2014
ORD Call Options Written -5,374 77.5000 American 16 Jan 2015
ORD Call Options Written -3,000 77.5000 American 17 Jan 2015
ORD Call Options Written -2,000 80.0000 American 30 May 2014
ORD Call Options Written -446,900 80.0000 American 21 Jun 2014
ORD Call Options Written -12,700 80.0000 American 19 Jul 2014
ORD Call Options Written -128,200 80.0000 American 18 Oct 2014
ORD Call Options Written -122,700 80.0000 American 17 Jan 2015
ORD Call Options Written -500 80.0000 American 15 Jan 2016
ORD Call Options Written -57,700 82.5000 American 21 Jun 2014
ORD Call Options Written -2,500 82.5000 American 18 Oct 2014
ORD Call Options Written -2,300 82.5000 American 17 Jan 2015
ORD Call Options Written -871,200 85.0000 American 21 Jun 2014
ORD Call Options Written -55,000 85.0000 American 19 Jul 2014
ORD Call Options Written -783,200 87.5000 American 21 Jun 2014
ORD Call Options Written -100 87.5000 American 19 Jul 2014
ORD Call Options Written -2,500 87.5000 American 18 Oct 2014
ORD Call Options Written -145,900 90.0000 American 21 Jun 2014

3. AGREEMENTS TO PURCHASE OR SELL ETC.

Full details should be given so that the nature of the interest or position can be fully understood:

It is not necessary to provide details on a Supplemental Form (Open Positions) with regard to contracts for differences (“CFDs”) or spread bets.

The currency of all prices and other monetary amounts should be stated.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Copyright Business Wire 2014

12345678910
Date   Source Headline
2nd May 20247:00 amRNSCalquence combination improved PFS in 1L MCL
1st May 20243:00 pmRNSTotal Voting Rights
29th Apr 20247:05 amRNSTruqap recommended for EU breast cancer approval
29th Apr 20247:00 amRNSEnhertu improved PFS in HER2-low and ultralow
25th Apr 20247:00 amRNS1st Quarter Results
11th Apr 20245:30 pmRNSResult of AGM
11th Apr 20247:00 amRNSAstraZeneca increases 2024 dividend by 7%
8th Apr 20247:00 amRNSEnhertu approved in US for HER2+ solid tumours
5th Apr 20247:00 amRNSImfinzi improved OS & PFS in limited-stage SCLC
2nd Apr 20243:00 pmRNSTotal Voting Rights
2nd Apr 20247:05 amRNSVoydeya approved in US
2nd Apr 20247:00 amRNSFDA accepts Dato-DXd BLA for breast cancer
25th Mar 20247:00 amRNSUltomiris approved in the US for NMOSD
19th Mar 20247:00 amRNSAstraZeneca to acquire Fusion
14th Mar 20247:00 amRNSAstraZeneca to acquire Amolyt
12th Mar 202411:00 amRNSDirector/PDMR Shareholding
7th Mar 202411:00 amRNSNotice of AGM
6th Mar 20243:05 pmRNSDirector/PDMR Shareholding
6th Mar 20243:00 pmRNSDirector/PDMR Shareholding
4th Mar 20247:00 amRNSEMA validates Dato-DXd MAAs for NSQ NSCLC and BC
1st Mar 20243:00 pmRNSTotal Voting Rights
26th Feb 20247:00 amRNSVoydeya recommended for EU approval
22nd Feb 20241:15 pmRNSAcquisition of Gracell completed
22nd Feb 202411:00 amRNSDirector/PDMR Shareholding
22nd Feb 20247:00 amRNSAstraZeneca prices a $5bn bond offering
21st Feb 20247:00 amRNSFiling of Form 20-F with SEC
20th Feb 202411:00 amRNSAnnual Financial Report
19th Feb 20243:00 pmRNSAstraZeneca completes acquisition of Icosavax
19th Feb 20247:10 amRNSTagrisso plus chemo approved in US for lung cancer
19th Feb 20247:05 amRNSFDA accepts Dato-DXd BLA for nonsquamous NSCLC
19th Feb 20247:00 amRNSTagrisso improved PFS in Stage III lung cancer
8th Feb 20247:00 amRNSFinal Results
1st Feb 20243:00 pmRNSTotal Voting Rights
2nd Jan 20243:00 pmRNSTotal Voting Rights
27th Dec 20237:00 amRNSAstraZeneca acquires Gracell
22nd Dec 20237:00 amRNSWainua (eplontersen) granted first US FDA approval
14th Dec 20233:00 pmRNSDirector/PDMR Shareholding
12th Dec 20237:05 amRNSAstraZeneca to acquire Icosavax
1st Dec 20233:05 pmRNSBlock listing Interim Review
1st Dec 20233:00 pmRNSTotal Voting Rights
1st Dec 20237:00 amRNSDiscontinuation of two CRYSTALIZE evidence trials
23rd Nov 20233:00 pmRNSDirector/PDMR Shareholding
17th Nov 20237:00 amRNSTruqap approved in US for HR+ breast cancer
14th Nov 20237:05 amRNSUpdate on PACIFIC-2 Phase III trial for Imfinzi
9th Nov 20233:00 pmRNSDirector Declaration
9th Nov 20237:10 amRNSImfinzi combination improves PFS in liver cancer
9th Nov 20237:05 amRNSAgreement with Eccogene for clinical stage GLP-1RA
9th Nov 20237:00 amRNS9M and Q3 2023 results
1st Nov 20233:00 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNSAstraZeneca cell & gene therapy deal w/ Cellectis
12345678910

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.